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Background: Moderate-to-severe psoriasis is associated with an increased risk of atherosclerotic cardiovascular
disease (ASCVD); however, the link is poorly understood.
Methods: Skin and serum from patients with psoriasis were evaluated to understand if there was evidence of
dysregulation in a targeted group of inflammatory and lipid genes related to ASCVD. Microarray analyses of
expression of targeted ASCVD genes from skin in 89 patients with moderate-to-severe psoriasis from the ACCEPT
trial were compared with non-diseased skin from healthy controls (n = 25). Serum (n = 149) was tested at baseline
for monocyte chemoattractant protein-1 (MCP-1), macrophage-derived chemokine (MDC), and apolipoprotein-A1
(Apo-A1) comparing to healthy controls (n=162).
Results: An increase in skin gene expression for MCP-1 (7.98-fold) and MDC (6.66-fold) (p < 0.001 each) was observed
in lesional versus healthy skin. Significant decreases in liver X receptor-alpha (LXR-α) (−5.94-fold), a protective
lipoprotein metabolism gene, and in peroxisome proliferator-activated receptor-alpha (PPAR-α) (−7.58-fold), a
protective anti-inflammatory and lipid modulating gene, were observed in lesional versus healthy skin (p < 0.001 each).
Serum analyses revealed that MCP-1 (502 vs. 141 pg/mL) and MDC (1240 vs. 409 pg/mL) levels were significantly
elevated in psoriasis compared with healthy controls (p < 0.001 each). Dysregulated lipid metabolism was also evident
in the serum, as Apo-A1, a protein product related to PPAR-α activation, was significantly decreased in patients with
psoriasis compared with healthy controls (25.2 vs. 38.9 mg/dL; p < 0.001).
Conclusions: Analyses of targeted genes and their products known to be associated with ASCVD revealed
dysregulation of inflammatory (MCP-1 and MDC) and lipid metabolism (LXR-α, PPAR-α) genes in psoriasis. These
findings provide evidence of a potential shared pathophysiology linking psoriasis to cardiometabolic diseases.
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Psoriasis is a chronic, inflammatory skin disease that
places some patients at increased risk of myocardial in-
farction [1], stroke [2], cardiovascular (CV) death [3],
overall mortality [4], and other major adverse CV events
[5]. The cause for this increased CV risk in psoriasis re-
mains unknown, although evidence suggests shared in-
flammatory pathways in psoriasis and atherosclerosis [6].
Macrophage-derived chemokine (MDC) and monocyte
chemotactic protein-1 (MCP-1) are involved in the traffick-
ing of activated T-lymphocytes to inflammatory sites.
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reproduction in any medium, provided the ordendritic cells, and natural killer cells, which are involved
in atherosclerosis and psoriasis, providing a potential link
to these two chronic diseases [7]. The skin is a lipid-rich
organ which expresses nuclear hormone receptors includ-
ing liver X receptor (LXR) and peroxisome proliferator-
activated receptor (PPAR), which may be dysregulated in
psoriasis [8]. LXR is a key regulator of reverse cholesterol
transport of lipids from atherosclerotic plaques back to the
liver [9] and is important in inflammation and insulin re-
sistance. PPARs are important in lipid metabolism [10].
PPAR-α is the target of fibrate drugs that raise high
density-lipoprotein (HDL), as well as production of apoli-
poprotein A1 (Apo-A1), the major lipoprotein of HDL [11].
Building on our observations from pathway analysis of
lesional versus nonlesional skin gene expression [12], weLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease (ASCVD) to evaluate expression of these se-
lect genes in the skin and serum from patients with
psoriasis. We hypothesized that ASCVD genes related
to inflammation in lesional skin from patients with
moderate-to-severe psoriasis may lead to systemic
manifestation of inflammation by dysregulated expres-
sion of the inflammatory and lipoprotein metabolism
proteins in the serum.
Methods
Populations studied
ACCEPT was a Phase 3, multicenter, randomized, active-
controlled, parallel, 3-arm study of patients with moderate-
to-severe plaque psoriasis to investigate the effects of an
anti-IL-12/23p40 mAb (ustekinumab) compared to anti-
TNF therapy (etanercept) [13]. Here, we compare serum
analyses and expression of ASCVD-related genes between
psoriatic skin (lesional and macroscopically normal
nonlesional skin) in patients from the ACCEPT trial who
underwent skin biopsies versus two separate healthy, non-
psoriatic control populations (one for skin analyses [n = 25]
and one for serum analyses [n = 162]). Microarray data
from the biopsy substudy of the ACCEPT trial [13] were
used for comparison of baseline lesional and nonlesional
skin in 89 psoriasis patients from the ACCEPT trial to
healthy skin (n = 25). Skin samples from 25 healthy sub-
jects (controls) who were selected to match in age and gen-
der with the psoriatic cohort in the skin biopsy analysis
were obtained from Rockefeller University (New York,
NY, USA) under institutional review board-approved
written informed consent. Serum samples were
obtained from 162 healthy volunteers (Bioreclimation,
Hicksville, NY, USA) with written informed consent
and a subset of 149 patients with psoriasis from the
ACCEPT trial. There was not a complete overlap of
the patients assessed for serum protein expression
and skin biopsy analysis in the ACCEPT trial. Of the
149 patients with psoriasis assessed for serum protein
expression, 62 were also part of the skin biopsy
substudy and this was a randomly selected subset.
Patients with psoriasis did not have any clinical CV
disease.
Skin biopsy analysis
Skin biopsies were isolated from a representative psoriatic
target lesion (3 cm) and identified as lesional psoriatic
skin. Nonlesional skin biopsies were obtained from a simi-
lar body area to the psoriasis lesion (i.e., arm, arm or leg,
leg) in the same method as lesional skin was obtained.
RNA was extracted with the RNeasy Fibrous Tissue Mini
Kit (QIAGEN Inc., Valencia, CA, USA). Microarray
hybridization was conducted using GeneChip HG-U133
Plus 2.0 arrays (Affymetrix, Santa Clara, CA, USA).Serum analysis
Serum (n = 149; including 62 patients from the biopsy
substudy) was tested at baseline for cytokines and
chemokines (MCP-1 and MDC), C-reactive protein
(CRP), and plasma Apo-A1 using a Luminex-based
platform (HumanMAP®, Myriad RBM, Inc., Austin,
TX, USA). Sixteen of the 43 candidate genes had pro-
tein products measured in serum, including CD40-
ligand, myeloperoxidase, MCP-1, PAI1, MDC, TNF-α,
IL-18, leptin, TNF-β, Apo-A1, IFN-γ, apolipoprotein-
CIII, MMP-9, IL-6, PAPPA, and adiponectin. Raw data
were log-transformed to achieve normal distribution of
the data prior to analyses.
Statistical analyses
Summary statistics were used to describe sample demo-
graphics. Normalization, quality control, and analysis of
the microarray data were conducted using Array Studio
v6.0 (OmicSoft Corporation, Cary, NC, USA). Gene ex-
pression data were normalized by GC-RMA and
transformed by log2 scale for data analysis. Microarray data
quality was assessed by Pearson’s correlation and Principle
Component Analysis. Significant modulations of the
targeted genes related to ASCVD between paired lesional
and nonlesional samples were identified by general linear
model. Subject was included in the model as a random
factor. Differences in serum protein levels were tested
using t-tests for normally distributed variables and by
Kruskal-Wallis testing for non-normally distributed
variables. Multiple testing correction (false discovery
rate <5%) was applied to both microarray and serum
analyses. We examined the correlation of baseline
psoriasis disease severity as measured by Psoriasis Area
and Severity Index (PASI) score and serum protein ex-
pression using Spearman’s correlation.
Results
Baseline demographics and disease characteristics
Baseline demographics and disease characteristics of the
patients with psoriasis are shown in Table 1. In addition,
162 healthy control subjects, of similar age, race, sex,
and mostly free of CV disease risk factors, were assessed
for serum protein expression.
Gene expression of targeted ASCVD genes related to lipid
metabolism and inflammatory genes differs between
healthy skin, psoriatic nonlesional and lesional skin
Genes linked to cardiometabolic pathways were assessed
by microarray for expression. A total of 43 genes chosen
a priori to be related to the pathophysiology of athero-
sclerosis, metabolic, or inflammatory dysregulation were
assessed in normal, nonlesional, and lesional skin sam-
ples. Of the 43 selected genes, 24 were differentially
expressed at a nominal level in psoriasis lesions compared
Table 1 Baseline demographic and disease characteristics
of patients with psoriasis
Randomized patients, n 149
Age, years, Mean ± SD 46.3 ± 12.8
Sex
Men, n (%) 114 (76.5)
White, n (%) 133 (89.3)
Psoriasis body surface area involvement, Mean ± SD 29.5 ± 18.6
Psoriasis Area and Severity Index (PASI) score,
Mean ± SD
21.3 ± 9.0
Psoriatic arthritis, n (%) 38 (25.5)
Body Mass Index (BMI), n (%)
N 148
Normal (BMI <25) 29 (19.6)
Overweight (BMI ≥25 and <30) 46 (31.1)
Obese (BMI ≥30) 73 (49.3)
Metabolic Syndrome, n (%)a 41 (27.5)
Cigarette smoking, n (%)
Current 50 (33.6)
Past or current 97 (65.1)
Relevant medical history, n (%)
ASCVDb 6 (4.0)
Diabetes mellitus 21 (14.1)
Hypertension 41 (27.5)
Hyperlipidemia 31 (20.8)
Family history of early ASCVD 15 (10.1)
High-density lipoprotein (HDL), n 141
Mean ± SD 47.9 ± 12.9
HDL <40 mg/dL, n (%) 43 (30.5)
Low-density lipoprotein, n 137
Mean ± SD 113.1 ± 35.7
Triglycerides, n 141
Median (IQ range) 134.0 (99.0, 182.0)
Total Cholesterol, n 141
Mean ± SD 191.8 ± 40.0
Total Cholesterol/HDL, Mean ± SD 4.3 ± 1.4
ASCVD atherosclerotic cardiovascular disease, IQ interquartile range.
aMetabolic syndrome is defined using modified National Cholesterol Education
Program criteria (waist circumference was replaced with BMI ≥ 30) including
the presence of 3 or more of the 5 risk factors: BMI ≥ 30; fasting triglycerides ≥
150 mg/dL; fasting HDL < 40 mg/dL (male) or HDL < 50 mg/dL (female);
baseline systolic pressure ≥ 130 mmHg, baseline diastolic pressure ≥ 85 mmHg,
or treatment for hypertension; fasting glucose ≥ 100 mg/dL
bASCVD is defined as having a baseline medical history of myocardial
infarction, coronary artery bypass, stroke, transient ischemic attack, or
peripheral vascular disease
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heatmap (Figure 1) demonstrated a pattern for a cluster of
lipid metabolism-related genes that were upregulated in
healthy skin, downregulated in nonlesional skin, andfurther downregulated in lesional skin. The opposite was
observed for a cluster of inflammation-related genes. In
particular, two chemotactic genes involved in psoriasis
and atherosclerosis (MCP-1 and MDC) were upregulated
in comparisons between lesional and normal skin and be-
tween nonlesional and normal skin. LXR-α and PPAR-α
expression was downregulated (Figure 2). No correlation
between the PASI score and MCP-1 or MDC expression
was observed. However, there was negative correlation of
PASI score with PPAR-α (r = −0.27, p = 0.013) and Apo-
A1 (r = −0.23, p = 0.034) expression, and no correlation
between PASI and MCP-1 (r = 0.13, p = 0.23) expression.
Protein levels of inflammatory, chemotactic, and
lipoproteins differ between patients with psoriasis and
healthy controls
Serum samples were analyzed to evaluate if targeted
genes associated with CV disease in the skin were also
associated with pathways in the blood (Figure 3). Sixteen
of the 43 genes had protein products measured in serum.
Among them, 10 of the 16 were differentially expressed at
a nominal level (Additional file 1: Table S2). CRP levels
were higher in patients with psoriasis compared with con-
trols (mean CRP 6.68 mg/L vs. 4.97 mg/L; p < 0.001).
Proteins associated with CV disease, MCP-1 (502 pg/mL
vs. 141 pg/mL) and MDC (1240 pg/mL vs. 409 pg/mL),
were elevated in patients with psoriasis compared with
controls (p < 0.001 each). Finally, we observed evidence of
dysregulated lipid metabolism, as indicated by a decrease
in Apo-A1 in patients with psoriasis (25.2 mg/dL),
compared with controls (38.9 mg/dL; p < 0.001). When
evaluating if psoriasis disease severity (PASI score) was
associated with inflammatory-related and CV disease-
related proteins in the blood, it was noted that PASI
strongly correlated with serum levels of MDC (r = 0.59,
p < 0.001) and CRP (r = 0.27, p = 0.001). There was a
weak, non-significant, relationship between PASI and
MCP-1 levels in the blood (r = 0.14, p = 0.08), with no
significant correlation with Apo-A1 (r = −0.07, p =
0.34).
Discussion
We report that a targeted group of genes related to ASCVD
(MCP-1, MDC, LXR-α, and PPAR-α) are dysregulated in
the skin of patients with psoriasis. Corresponding proteins
and downstream products (MCP-1, MDC, Apo-A1) also
were modulated in the serum. Lesional psoriatic skin
demonstrated greater dysregulation of these pathways
compared with nonlesional psoriatic skin and normal
control skin. Additionally, corresponding serum ana-
lyses of MCP-1, MDC, and Apo-A1 were modulated in
expected directions consistent with ASCVD findings,
suggesting that abnormal skin function may be a po-







































































Figure 1 Expression profile of 43 targeted cardiovascular, metabolic, and inflammatory-related genes in healthy normal, nonlesional,
and lesional skin samples at baseline. CCL2 = MCP-1; CCL22 =MDC; NR1H3 = LXR.
Mehta et al. Journal of Translational Medicine 2013, 11:194 Page 4 of 8
http://www.translational-medicine.com/content/11/1/194Our findings are consistent with a recent report [14]
demonstrating modulation of genes involved in inflam-
mation and lipid metabolism. In addition to examining
serum from patients with psoriasis, we also analyzed
inflammatory genes associated with CV diseases [15].
Induction of MCP-1 and MDC in psoriatic skin oc-
curred in a linear increase, with healthy skin showing
no expression, nonlesional psoriatic skin having some
expression, and psoriatic lesional skin having the
highest expression. Interestingly, we observed signifi-
cant downregulation of LXR-α and PPAR-α, genes in-
volved in atherosclerosis, inflammation, and HDL
metabolism, which we hypothesized a priori would be mod-
ulated in psoriatic skin. LXR-α regulates ABCA1 (ATP-
Binding Cassette, subfamily A, member 1) and ABCG1, two
key transporters of cholesterol in atherosclerotic lesions [9]and inflammatory pathways downstream of nuclear factor
kappa-B [10]. PPAR-α regulates the expression of genes
involved in cell proliferation, lipid metabolism, and in-
flammation, including Apo-A1, ABCA1, and HDL.
Prospective cohort and small cross-sectional studies
have demonstrated that psoriasis is associated with lower
HDL levels [16]. Based on animal models, decreased
concentration of HDL due to systemic inflammatory
suppression leads to decreased hepatic production of
Apo-A1. Our findings suggest that skin inflammation
may be involved in the suppression of serum HDL and
Apo-A1 concentrations, given that PPAR-α and LXR-α
are downregulated in lesional and nonlesional skin of
patients with psoriasis and that this was observed to a
greater extent in patients with more severe skin involve-




















































































































































Figure 2 Microarray skin expression of (A) monocyte chemotactic protein-1 (MCP-1), (B) macrophage-derived chemokine (MDC), (C)
liver X receptor-alpha (LXR-α), and (D) peroxisome proliferator-activated receptor-alpha (PPAR-α) between healthy controls (normal
skin) and patients with psoriasis (lesional and nonlesional skin) at baseline. The array contains specific isoforms of genes depicted.
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pression in the skin.
Our preliminary examination of the systemic circulation
corroborated the previous report of complex two-way in-
teractions between activated dendritic cells, T-cells, and
keratinocytes mediated by blood cytokines and chemokines
[14]. Corresponding to the increased gene expression of
MCP-1 and MDC, we observed a significant increase inthese gene products in the serum related to disease severity
(i.e., PASI). Levels of these proteins are associated with CV
disease [17] and are integrally involved in trafficking in-
flammatory cells to areas of vascular inflammation [18], a
phenotype that is enriched in psoriasis [19].
Additionally, we confirmed the hypothesized decrement
in serum Apo-A1 levels in psoriasis compared with con-






















































Figure 3 Microarray serum expression of (A) C-reactive protein (CRP), (B) monocyte chemotactic protein-1 (MCP-1), (C) macrophage-
derived chemokine (MDC), and (D) apolipoprotein-A1 (Apo-A1) between healthy controls (normal serum) and patients with psoriasis
(psoriasis serum) at baseline.
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verse cholesterol transport, which was recently demon-
strated to be decreased in psoriasis [20]. This association
of decreased gene expression of LXR-α and PPAR-α may
provide a potential mechanistic insight linking low HDL
levels, psoriasis, and ASCVD.
Our study has several limitations. We cannot conclude
that inflammation and dysregulation of metabolic genesin the lesional skin are primarily driving the CV risk in
patients with psoriasis. However, the findings suggest
that modulating known CV and metabolic genes in the
skin may in part explain the observed increased risk of
ASCVD in severe psoriasis. Furthermore, we do not
have atherosclerotic plaque microarray gene expression
from patients with psoriasis to complete our explanatory
model. Because access to atherosclerotic plaque in a
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rely on serum proteins as surrogate markers to deduce
the effect of skin on atherosclerosis. We also did not
have specific CV demographic profiles for healthy sub-
jects who provided serum for the study. We are limited
by the lack of complete demographic data for the
healthy serum samples, namely BMI, given the high
prevalence of obesity in the patients with psoriasis.
However, it is unlikely that these differences are driving
the observed differences in protein levels due to the low
correlation rate between BMI and the four protein levels
of interest (data not shown). Our clinical trial may not be
generalizeable to the larger psoriasis population; however,
this study includes the largest population of patients with
moderate-to-severe psoriasis with characterization of skin
gene expression with simultaneous serum analytes im-
portant in CV disease. Confirmatory studies of skin
microarray gene expression with RT-PCR analysis were
not performed as others had reported [14]; however, they
reported a high concordance between microarray and
real-time PCR, both in psoriasis [14] and in other studies
[21,22]. In addition, one control sample population was
used for skin biopsy analyses and the other control popu-
lation was utilized for serum samples. We did not have
concurrent samples in the control population.
Here we provide evidence of gene dysregulation within
the skin and serum in patients with psoriasis, supporting
a shared pathophysiology of psoriasis and ASCVD [23].
Future studies may help to address an in vivo link be-
tween psoriasis and vascular inflammation using im-
aging, and by focusing on the effect of psoriasis
treatment on CV biomarkers.Additional file
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